Uncategorized
Acucela Shareholders Elect New Board Members
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that shareholders have elected four new members to the Company’s Board of Directors (the “Board”) at today’s special meeting of the Company’s shareholders (the “Special Meeting”). At the Special Meeting,
